Project Grant R43CA291415
Award Date
9/13/24
Completion Date
8/31/25
Dollars Obligated
$799K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
The National Cancer Institute (NCI) awarded a $222,998 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of California, San Diego (UCSD) for the period of March 10, 2025 to February 28, 2027. The grant supports research to engineer endogenous immune cells, including T cells, NK cells, and macrophages, to express chimeric antigen receptors (CARs) using a novel virus-like particle (VLP) vector. The goal is to enable these engineered immune cells to mediate...
The National Cancer Institute (NCI), through the Cancer Treatment Research program (CFDA 93.395), awarded a $1,999,703 project grant to March Biosciences Inc. to develop dual-targeting allogeneic chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL). The 2-year project aims to engineer partially-matched donor-derived CAR-T cells targeting both CD5 and CD7 antigens, which are expressed in...
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
This $107,948 Project Grant awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) will fund the development of tunable, microenvironment-responsive CAR T cells to enhance the potency and safety of solid tumor CAR T cell therapy, with a focus on ovarian cancer. The research aims to engineer a hypoxia biosensor circuit in primary human T cells to enable targeted CAR expression and cytokine delivery within the tumor microenvironment, thereby improving anti-tumor efficacy...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is providing $748,337 to Pyrojas Inc. to develop an innovative "Pyrotimer" CAR-T cell therapy. The goal is to create a more potent and persistent CAR-T cell treatment that can overcome the immunosuppressive tumor microenvironment, particularly by inhibiting transforming growth factor-beta (TGF-β). The research plan involves extensive in vitro and in vivo...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $627,272 project grant to The Johns Hopkins University on Feb 24, 2025 to develop and optimize engineered, self-propelled tumor-infiltrating CAR T cells using synthetic cytokine receptors (velocity receptors) to enhance their migration speed and tumor infiltration capabilities. The goal is to improve the efficacy of CAR T cell therapy for treating pancreatic cancer, which has a 5-year survival rate of just ~12%....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,958 to Mabswitch Inc., a minority-owned small business, to assess the feasibility of regulating the activation, effector functions, and cytokine release of chimeric antigen receptor (CAR) T-cell therapies. The project aims to develop a "switchable affinity CAR" (SAEFCAR) that can be controlled by an exogenously administered ligand, potentially mitigating the toxicity...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $1,313,806.00 in funding from August 13, 2024 through July 31, 2029. The grant supports the development and clinical translation of mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapies for solid tumors. Key objectives include: Elucidating the mechanisms by which the KITV costimulatory domain enhances CAR T-cell...